Low levels of expression of tolerance‐inducing TGFB have been reported in experimental autoimmune encephalomyelitis, the murine model of neuroinflammation used to study MS, with increased expression after treatment with the disease modifier, fingolimod.23 Also, in PBMCs from patients with established disease, TNF mRNA levels are higher and IL‐10 and TGFB levels are lower during relapse, and this balance is inverted during stable disease.24 Here, TGFB1 is linked to myeloid sarcoma.